


Respiratory Pathogens Data Oct 6 2018 - Jan 11 2019

Week Beginning	InfA-H1	InfA-H3	2009 H1N1	Inf B	RSV	All Para	EV/ Rhino	Meta pneumo	Adeno	All Corona	Bocca	Mycoplasma	Chlamydia	Total Pos	POS FLU	Total	ACL %FLU	US %FLU	IL/WI PCR	Sofia EIA
Jan 11	0	4	22	1	128	12	70	17	10	45	4	6	1	320	27	1026	2.6	n/a	n/a	10.6
DEC 28	0	4	22	1	128	19	87	21	14	41	4	5	0	346	27	812	3.3	12.7	11.8	9.6
DEC 28	0	5	11	3	105	18	92	15	12	35	11	3	1	311	19	783	2.4	13.7	9.0	9.0
DEC 21	0	2	13	0	105	19	72	10	8	21	10	1	0	261	15	766	2.0	15.6	6.9	6.9
DEC 14	0	0	4	0	55	22	54	3	8	6	6	2	0	160	4	891	0.4	11.0	4.1	5.1
DEC 7	0	0	2	0	63	26	58	9	10	8	2	3	2	183	2	785	0.3	3.6	1.8	3.6
Nov 30	0	0	1	0	42	25	71	9	8	9	5	4	1	175	1	641	0.6	4.2	1.9	1.9
NOV 23	0	2	2	0	51	29	83	5	10	4	3	4	0	193	4	566	0.7	2.4	1.6	2.7
NOV 16	1	0	0	0	25	29	92	3	5	1	4	4	0	164	1	457	0.2	1.7	1.5	0.7
NOV 9	0	0	1	0	23	28	78	4	7	5	1	6	2	155	1	458	0.2	1.2	0.9	1.5
OCT 26	0	0	2	0	18	23	93	1	8	2	3	6	1	157	2	506	0.4	0.9	0.7	1.6
OCT 19	0	0	1	0	12	25	93	1	5	3	3	6	0	149	1	415	0.2	0.8	0.5	1.3
OCT 12	0	0	0	0	11	17	111	1	4	3	0	1	1	149	0	478	0.0	0.6	0.4	1.0
OCT 6	0	0	1	0	4	15	101	2	5	1	2	2	0	133	1	435	0.2	0.8	0.5	1.5


Flu PCR
% Rate

ACL RESP. PANEL - POSITIVITY RATE All viruses - 31.2 %


- All Corona
- Chla mydia
- Myco plasma
- All Para
- Adeno
- Meta pneumo
- EV / Rhino
- RSV
- Inf B
- InfA-H3
- 2009 H1N1
- InfA-H1
- Bocca



ACL RESP. PANEL - Flu PCR - 2.6%, Flu EIA - 10.6%



ACL RESP. PANEL - RSV PCR - 12.5%, RSV EIA - 7.5%




Correlation between RPPNL (FLU PCR) and Sofia (FLUAG) - Accuracy 98.3%

In the last two months 1288 samples were tested by both methods most of them negative, 19/31 samples were positive by EIA when confirmed by PCR. 12 negative EIA samples were tested positive by PCR method. (ACL correlation data is compiled on samples collected within <48 h)

Nov 11 2018 to Jan 11 2019				
FLUAG (Sofia) vs RPPNL (PCR) correlation				
		RPPNL		
		+	-	Total
FluAG	+	19	6	25
	-	12	1251	1263
		Total		1288
%				
61.3	Clinical Sensitivity			
99.5	Clinical Specificity			
76.0	Positive Predictive Value (PPV)			
99.0	Negative Predictive Value (NPV)			
98.6	Accuracy			

Jan 5, 2018 **Positivity rate 12.7%** - Flu A – 97% , Flu B – 3%


Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2018-2019 Season



A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists*

Week Ending Jan 05, 2019 - Week 1



*This map indicates geographic spread and does not measure the severity of influenza activity.

Data Reported to ILINet

2018-19 Influenza Season Week 1 ending Jan 05, 2019



ILI Activity Level



*This map uses the proportion of outpatient visits to healthcare providers for influenza-like illness to measure the ILI activity level within a state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high activity levels.


*Data collected in ILINet may disproportionately represent certain populations within a state, and therefore may not accurately depict the full picture of influenza activity for the whole state.

*Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map are based on reports from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received.


*Differences in the data presented by CDC and state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.

*For the data download you can use Activity Level for the number and Activity Level Label for the text description.


The most prevalent target as Dec 31 2018 were HSV 2 and HSV 1 – total pos. rate 10.9%




The most prevalent bacterial targets as Dec 31 2018 was Giardia



The most prevalent virus target as **Dec 31 2018** was **Norovirus type I / II** – **15%** pos. rate



	BV-Bacterial vagionosis	Candida albicans	Candida galbrata	Candida kruzei	T. vaginalis	M. genitalium	M. hominis	U. parvum	TOTAL % POS
% pos	22.2	13.1	1.9	0.3	3.0	0.1	7.2	17.5	65.3



Neuraminidase Inhibitors Resistance in samples collected – as of Jan 5, 2019

Per CDC website	Oseltamivir		Peramivir		Zanamivir	
	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)
Influenza A (H1N1)pdm09	302	0	302	0	302	0
Influenza A (H3N2)	141	0	141	0	141	0
Influenza B	53	0	53	0	53	0

There no resistance detected.